INTRODUCTION
The human immunodeficiency virus type I (HIV-1) can infect different cell types of the immune system, but preferentially targets proliferating CD4 + T lymphocytes. Once the viral DNA is integrated into the host cell genome, regulation of HIV-1 gene expression depends on the cellular transcription machinery. Transcription initiation is controlled by the viral promoter that is located in the U3 region of the long terminal repeat (LTR). The promoter encodes numerous transcription factor binding sites (TFBSs) that are bound by specific cellular transcription factors, which either induce or repress transcription (Pereira et al., 2000) . The core promoter (278 to 21, relative to the transcription start site at +1) plays a crucial role in HIV-1 transcription as deletion of the three SP1 sites, or the two NF-KB binding sites, severely impairs or even abolishes viral replication (Berkhout & Jeang, 1992; Kamine et al., 1991; Nabel & Baltimore, 1987; Ross et al., 1991) . A low level of basal transcription is triggered by host TFs, but high levels of HIV-1 gene expression and subsequent virus production require the viral Tat protein. Tat interacts with the trans-activation-response region (TAR) element, an RNA motif located at the 59 end of each HIV transcript (Berkhout et al., 1989) . This interaction facilitates association of the positive transcription elongation complex-b (P-TEFb), which is composed of cyclin-dependent kinase 9 (CDK9) and cyclin T1 (Marshall & Price, 1995) . P-TEFb mediates hyperphosphorylation of the carboxy-terminal domain of RNA polymerase II, thereby strongly enhancing its elongation efficiency (Isel & Karn, 1999; Wei et al., 1998) . If the HIV-1 promoter is not sufficiently active to support the production of a threshold amount of Tat protein, this can result in a latent HIV-1 provirus (Donahue & Wainberg, 2013; van der Sluis et al., 2013a; Van Lint et al., 2013) .
Synthesis of the initial Tat protein molecules in an HIV-1 infected cell requires a basal level of transcription triggered by binding of cellular transcription factors to the LTR. Each HIV-1 subtype has a specific LTR promoter configuration and even minor sequence changes in TFBSs or their arrangement can strongly influence transcriptional activity, thereby affecting viral replication and latency properties (Crotti et al., 2007; Koken et al., 1992; Montano et al., 1997; Naghavi et al., 1999; Roof et al., 2002) . In a previous study, we constructed a set of isogenic viruses with subtypespecific promoter elements to investigate these functions (Centlivre et al., 2005 (Centlivre et al., , 2006 De Baar et al., 2000; Jeeninga et al., 2000; van der Sluis et al., 2011; van Opijnen et al., 2004a) . Activation of a latent HIV-1 provirus in HIV-1-infected T-cell lines was triggered by TNFa, which activates the transcription factor NF-KB. We reported no gross differences among the subtypes, except for subtype AE that combines an increased level of basal transcription with a reduced TNFa response. This subtype AE-specific transcription profile was linked to the presence of a unique GABP binding site, instead of the regular NF-KB binding site, in the AE LTR. In this study, we tested the set of HIV-1 variants for their latency properties in primary effector T lymphocytes instead of T cell-lines. We further enhanced the study by investigating the subtype B and AE promoters in more detail, using reporter constructs with the LTR promoter driving the expression of the luciferase gene.
RESULTS AND DISCUSSION
HIV-1 subtype-specific latency and replication properties in primary T lymphocytes
We used recombinant viral genomes with subtype-specific promoters inserted in the common backbone of the subtype B LAI isolate (De Baar et al., 2000; Jeeninga et al., 2000) . These recombinant LAI-A, -B, -C, -D, -AE, -F, -G and -AG viruses are isogenic except for the core promoter region that encodes the major TFBS, including two NF-KB and three Sp1 sites (Fig. 1a) . These subtype-specific viruses were previously tested for their latency properties in T-cell lines using a latency test following acute infection (van der Sluis et al., 2011) . Here, we investigated these viruses in primary proliferating T lymphocytes. The HIV-1 provirus can be activated from latency in T-cell lines with TNFa or other drugs that activate the NF-KB TF Duverger et al., 2009; Folks et al., 1989; Jeeninga et al., 2008; West et al., 2001; Williams et al., 2004) . However, purging provirus in these primary T lymphocytes requires coculturing of the HIV-1-infected T lymphocytes with dendritic cells (DCs) (van der Sluis et al., 2013b).
PHA-activated CD4
+ T lymphocytes were infected with equal amounts (based on CA-p24 quantification) of the subtype-LTR viruses. Unbound virus was washed away after 4 h and the cells were cultured in the presence of the fusion inhibitor T1249 to prevent new rounds of infection. Cultures were split after 24 h into a mock treated culture and a DC co-culture. After another 24 h the cells were harvested, fixed, stained and analysed by flow cytometry for surface CD3 and intracellular CA-p24 expression. The mock treated culture yielded 2.3 % CA-p24-positive cells for LAI-B (Fig. 1b) . Similar results were obtained for the other subtypes. Following co-culturing with DCs, the percentage of CA-p24-positive cells increased significantly for all subtypes and the fold activation of HIV-1-producing cells was calculated (Fig. 1c) van Opijnen et al., 2004a) . To investigate the influence of the subtype-specific promoter on viral replication capacity in primary T-cells, PHA-activated CD4 + T lymphocytes were infected with an equal amount of virus and replication was monitored by regular sampling of the culture supernatant for CA-p24 ELISA. Peak infection was reached 5 days post-infection for all subtypes (Fig.  2) . The combined results show no gross differences among the subtypes in their latency properties and replication efficiency in primary effector T lymphocytes.
We previously measured reduced latency for subtype AE in SupT1 cells, but this phenotype was not apparent in primary cells. The observed difference between primary cells and the SupT1 T-cell line might be explained by NFKB levels. SupT1 T cells display low levels of active NF-KB under standard culture conditions and are therefore very responsive to NF-KB activation via TNFa stimulation (Chen et al., 1997) . The primary cells were PHA activated prior to HIV-1 infection, which strongly activates the NF-KB pathway; thus, further enhancing this pathway with TNFa would have little effect. The AE LTR promoter is unique in that it contains a GABP site instead of the upstream NF-KB site, and is therefore less dependent on NF-KB activation, which may also explain the AE phenotype in SupT1 T cells. Activation of latent provirus in primary T cells by co-culture with DCs is triggered by a currently unknown signalling pathway, but probably does not involve NF-KB activation (van der Sluis et al., 2013b). Interestingly, subtype A displayed reduced activation from latency in primary cells, but did not exhibit a higher basal level of productive infection, suggesting either that this subtype establishes a smaller latent reservoir or that it was not efficiently purged from latency. Subtype A was recently reported to establish latent infections very efficiently in the Jurkat T-cell line (Duverger et al., 2013) , supporting the idea that subtype A may be less efficiently purged.
Subtype-specific promoter characteristics
To study the promoter characteristics of the set of HIV-1 subtypes in more detail, luciferase reporter constructs with the subtype-specific LTR promoter were used (Jeeninga et al., 2000) . HEK293T cells were transiently transfected with an LTR reporter (Fig. 3a) and a Renilla luciferase reporter plasmid to control for differences in transfection Transcription and latency properties of HIV-1 subtypes efficiency. We measured no significant differences for the different subtype LTRs in basal promoter activity, which was arbitrarily set at unity for each subtype to compare LTR induction among the subtypes (Fig. 3b) . To investigate NF-KB-induced LTR induction in the absence of Tat, the transfected cells were stimulated with TNFa. TNFa induction ranged from a modest fourfold activation for the subtype AE promoter to 12-fold for the subtype D promoter, with a mean ninefold activation for the subtype B promoter. Co-transfection with a Tat expression plasmid, without TNFa stimulation, induced the subtype B promoter 7.8-fold, while the other subtype LTRs showed induction ranging from fivefold for subtype AG to 14.5-fold for subtype AE. TNFa treatment in the presence of Tat further boosted the LTR promoter activity for all subtypes, with the lowest (13-fold) induction observed for subtype AG and the highest (36-fold) for subtype B. Thus, TNFa increased the basal promoter activity of all subtypes at a statistically significant level, but with a relatively low induction for subtype AE, as expected due to the lack of a second NF-KB site. Tat induction, on the contrary, is higher for AE compared with the other subtypes. Interestingly, subtype C, which was is predicted to have three NF-KB sites (Fig. 1a) , responded similarly to TNFa treatment as the other subtype LTRs with the regular two NF-KB sites.
The GABP binding site
Substitution of the regular upstream NF-KB site with a GABP site in subtype AE determines its unique transcriptional profile of reduced latency combined with increased basal transcription (Jeeninga et al., 2000; van der Sluis et al., 2011) . We therefore created new B and AE reporters in which these TFBSs were exchanged (Fig. 4a ). Luciferase assays indicated that the B and B+GABP reporters exhibit lower basal activity than the subtype AE and AE+26NFKB reporters. but the differences were not statistically significant (Fig. 4b) . The basal promoter activity was arbitrarily set at unity to compare the induction properties. Adding the GABP site to the subtype B LTR indeed reduced TNFa induction and increased Tat induction (Fig. 4c) . Conversely, adding the NF-KB site to AE restored TNFa induction and decreased Tat induction.
The putative AP-1 binding site
Another prominent difference between the B and AE promoters is a putative AP-1 binding site that partially overlaps the RBEIII binding site ( Fig. 1a ) (Jeeninga et al., 2000) . 'AP-1 transcription factor' is a collective term for a group of structurally and functionally related proteins that can bind to a DNA consensus sequence known as the TPAresponsive element (TRE: 59 TGA(C/G)TCA 39) (Meng & Xia, 2011) . AP-1 is involved in a broad range of cellular processes. Each of these proteins is differentially expressed in different cell types, meaning that every cell type has a unique profile of AP-1 dimers (Hess et al., 2004) .
To study the influence of this AP-1 binding site, mutations were created that either disrupt the AP-1 site in the subtype AE LTR (AE2AP1) or introduce the AP-1 site in the subtype B LTR (B+AP1, Fig. 5a ). The mutations were designed not to affect the conserved upstream RBEIII binding site but may have affected the TFII-I site that contributes to basal LTR promoter activity (Dahabieh et al., 2011; Koken et al., 1994; Malcolm et al., 2008; Sadowski & Mitchell, 2005) . The B+AP1 reporter consistently showed a slightly higher, though not statistically significant, basal promoter activity than the B reporter (Fig. 5b) , and the basal promoter activities for the AE2AP1 and wild-type AE LTR reporters were comparable, suggesting no major effects of the mutations on the TFII-I site in this setting. To compare induction of the LTR reporters, the basal promoter activity was set at unity. TNFa-mediated LTR induction decreased from 10.5-fold for B LTR to sixfold for B+AP1 (Fig. 5c) . Introducing the AP-1 site in the subtype B LTR also slightly decreased Tat induction, from 5.9-to 4.2-fold. Disruption of the AP-1 site in the subtype AE promoter did not affect TNFa and Tat responses.
The LTR constructs were next examined in a Tat titration experiment. Induction of the wild-type B LTR was apparent with increasing amounts of Tat, while B+AP1 remained mostly unaffected (Fig. 5d) . Tat equally enhanced transcription from the AE and AE2AP1 LTRs (Fig. 5e) . Thus, the introduction of AP-1 to the B LTR increased basal promoter activity, but decreased Tat induction. The equivalent mutations in subtype AE had little effect.
Expression of c-Jun
To investigate whether the AP-1 site is targeted by an AP-1 transcription factor, the reporter constructs were co-transfected with a vector encoding c-Jun, which belongs to the AP-1 family of transcription factors. Expression of the c-Jun protein was demonstrated by Western blotting of cell extracts (Fig.  6a) . Overexpression of c-Jun decreased basal promoter activity (i.e. without Tat) of the AE reporter (Fig. 6b) . Surprisingly, the promoter activity of subtype B also decreased (although this was somewhat less pronounced), even though it lacks the AP-1 consensus sequence. c-Jun expression decreased B+AP1 promoter activity more than that of the wild-type B LTR promoter. As expected, transcription of the AE LTR lacking the AP-1 site (AE2AP1) was hardly influenced by c-Jun overexpression. These results indicate that c-Jun inhibits the basal promoter activity of both the subtype B and AE LTR, but the consensus AP-1 site as present in subtype AE potentiates the suppression.
To investigate whether c-Jun also inhibits LTR promoter activity in the presence of Tat, the reporter constructs were co-transfected with the c-Jun expression vector and the Tat Transcription and latency properties of HIV-1 subtypes expression vector. c-Jun overexpression had no effect on Tat-induced induction of the subtype B LTR reporter (Fig.  6c) . Surprisingly, c-Jun increased Tat-mediated induction of the B+AP1, AE and AE2AP1 reporters. Thus, c-Jun enhances Tat-mediated LTR transcription but suppresses basal LTR transcription without Tat.
AP-1 and the different HIV-1 subtypes
Next, the other subtype LTRs were tested for c-Jun responsiveness. Like subtype AE, promoters of subtype C, G and AG are predicted to have a single AP-1 site, and subtypes A and F are predicted to have two ( Fig. 7a ) (Jeeninga et al., 2000) . HEK293T cells were transfected with an LTR reporter with and without the c-Jun expression plasmid. To compare the c-Jun effect, the basal activity of each LTR was arbitrarily set at unity. Although there was variation among the subtypes, c-Jun decreased the basal promoter activity of all LTR reporters (Fig. 7b) . However, the variation in c-Jun response could not be linked to the number of predicted AP-1 sites.
To test the effect of c-Jun in the presence of Tat, the reporters were co-transfected with the c-Jun and Tat expression vectors. As expected, c-Jun expression did not further enhance promoter activity of the 'AP-1-free' subtype B LTR in Tat-expressing cells (Fig. 7c) . The Tat Pertussis toxin B-oligomer increased FosB, Fra2 and ATF2 protein levels, and this correlated with decreased LTR promoter activity (Rizzi et al., 2006) . This was only observed for constructs containing the predicted AP-1 binding site. In this study we increased c-Jun protein levels, which directly influenced LTR promoter activity, but this may indirectly have affected endogenous levels of c-Jun Transcription and latency properties of HIV-1 subtypes binding partners as well. By overexpressing c-Jun, its homodimerization may become predominant, in this setting reducing HIV-1 promoter activity. Alternatively, Tat itself has been reported to change the composition of AP-1 dimers that bind to the IL2 promoter, thereby reducing its transcription (González et al., 2001 ). Thus, a further possibility could be that Tat changes AP-1 protein composition on the HIV LTR.
Concluding remarks
Our experiments show that the HIV-1 LTR is responsive to the c-Jun protein. This effect is strengthened when the LTR contains an AP-1 site that matches the TRE consensus more closely, as in subtype AE. Duverger et al. (2013) recently published a study proposing that the AP-1 binding site is an important determinant of viral latency as part of the latency establishment element. In this transcription study, c-Jun suppressed LTR activity in the absence of Tat, an intriguing result when one thinks of an infected cell where Tat protein does not reach the threshold for LTR induction, and c-Jun may thus contribute to the establishment of a latent provirus. Interestingly, c-Jun overexpression instead boosts LTR promoter activity in the presence of Tat. In other words, c-Jun provides the setting for Tat to act as a molecular switch of HIV-1 LTR activity that is both sensitive and dominant.
METHODS
Cells. The human embryonic kidney cell line HEK293T was grown as a monolayer in Dulbecco's minimal essential medium supplemented with 10 % (v/v) FCS, 40 U penicillin ml 21 , 40 mg streptomycin ml 21 and non-essential amino acids (Gibco) at 37 uC and 5 % CO 2 . For the isolation of CD4 + primary T lymphocytes and monocytes, human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats (Central Laboratory Blood Bank, Amsterdam, The Netherlands) by use of a Ficoll gradient. Monocytes were subsequently isolated with a CD14 selection step using a magnetic bead cell sorting system (Miltenyi Biotec). Purified monocytes were cultured in RPMI 1640 medium containing 10 % FCS and differentiated into DCs by stimulation with 45 ng interleukin-4 ml 21 (Biosource) and 500 U granulocyte macrophage colony-stimulating factor ml 21 (ScheringPlough) on days 0 and 2, and used on day 6 (van Montfort et al., 2008) . The remaining PBMCs were frozen in multiple vials. When required, the PBMCs were thawed, activated with 2 mg phytohaemagglutinin (PHA) ml 21 for 3 days' activation and cultured in RPMI medium supplemented with 10 % FCS and 100 U recombinant IL-2 (rIL-2) ml 21 (Novartis). On day 3 of culture, CD4 + T lymphocytes were enriched by depleting CD8 + T lymphocytes using CD8 immunomagnetic beads (Dynal; Invitrogen). The CD4 + T lymphocytes were cultured for 3 days in RPMI medium with rIL-2 and 10 % FCS.
Reagents. TNFa (PHC3015; Invitrogen) was prepared in sterile MilliQ H 2 O (stock solution 10 mg ml 21 ) and used at a final concentration of 10 ng ml
21
. The fusion inhibitor T1249 (WQEWEQKITA-LLEQAQIQQEKNEYELQKLDKWASLWEWF) was obtained from Pepscan and used at a final concentration of 0.1 mg ml 21 .
Antibodies. For intracellular CA-p24 FACS staining we used a-CA-p24-RD1 (clone KC57; Coulter). For CD3 staining, the APCconjugated a-CD3 (BD Bioscience) was used. For DC staining, purified a-CD83-APC (BD Bioscience), a-CD86-PE (BD Pharmingen), a-HLA-DR-PerCPCy5 (BD Bioscience), a-CD14-FITC (BD Bioscience) and a-DC-SIGN-PE (R&D Systems) antibodies were used. For protein detection on Western blot the mouse monoclonal anti-b-actin (Sigma), rabbit polyclonal anti-c-Jun (Abcam), goat anti-rabbit or goat antimouse HRP-labelled secondary antibodies (KPL) were used.
Plasmids. LTRs from patient isolates representing subtypes A, C, D, AE (CRF_01), F, G and AG (CRF_02) were selected as being representative of the viral quasi-species in the patient and the HIV-1 subtypes (De Baar et al., 2000) . The BseAI-AflII fragment (position 2147-163) of the LTR was exchanged in an LTR-luciferase plasmid that is based on the subtype B LAI sequence (Jeeninga et al., 2000) . Introduction of the GABP in place of the upstream NF-KB site in the promoter of subtype B and the conversion of the unique GABP in AE into a second NF-KB site in the full-length molecular clone pLAI (Peden et al., 1991) have previously been described (van der Sluis et al., 2011; Verhoef et al., 1999) . To introduce the B+GABP and AE+26NF-KB LTRs in the luciferase reporter constructs, the LTR was excised from pLAI with XhoI-BglI restriction enzymes and cloned into pBlue39LTR (Jeeninga et al., 2000) . From this intermediate plasmid the LTR was excised by restriction with BseAI-AflII and cloned into the LTR-luciferase plasmid using these sites.
To introduce the AP-1 site in the subtype B promoter, pBlue39LTR B was used as a template in two independent PCRs under standard conditions. PCR primers 59 GAA CTG CTG ACA AAG AAG TTG CTA C 39 and standard primer 1 (59 TGT CTC ATG AGC GGA TAC ATA 39) were used in reaction A (bold indicates the AP-1 site). Reaction B was done with primers 59 CTT CTT TGA CAG CAG TTC TTG AAG TAC 39 and standard primer 2 (59 TGG AAG GGC TAA TTC ACT CCC 39). Both PCR products, purified from gel, were used as templates in a third PCR under standard conditions with standard primers 1 and 2. The 833 bp PCR product was digested with BseA1 and HindIII, purified from gel and ligated into pBlue39LTR that was previously cut with the same enzymes. To remove the AP-1 site from the AE, promoter pBlue39LTR AE (Jeeninga et al., 2000) was used as a template in two independent PCRs under standard conditions. PCR primers 59 GAC TCG TGA CAT CGA AGT TTC TAA C 39and standard primer 1 were used in reaction A (bold indicates the mutated AP-1 site). Reaction B was done with primers 59 CTT CGA TGT CAG CAG TCT TTA TAG TAC 39 and standard primer 2. Both PCR products, purified from gel, were used as templates in a third PCR under standard conditions with standard primers 1 and 2. The 833 bp PCR product was digested with BseA1 and HindIII, purified and ligated into pBlue39LTR that had previously been cut with the same enzymes. The mutated LTRs were cloned from the pBlue39LTR vector into the luciferase plasmid using the BseAI-AflII restriction sites, or into the full-length molecular clone pLAI with XhoI-BglI restriction sites. All new constructs were verified by sequencing.
The pTat exon contains the Tat coding sequence under control of the constitutive cytomegalovirus (CMV) promoter (Verhoef et al., 1997) .
To control for transfection efficiency, the pRL-TK (GenBank accession number AF025846) plasmid (Invitrogen) is used. In this plasmid the Renilla ORF is under the constitutive expression of the TK promoter that is not affected by TNFa treatment as the promoter does not have an NF-KB binding site.
For c-Jun expression, the full-length cDNA clone of the JUN gene (IRATp970B0488D) was excised from pBluescriptR (BioScience) with EcoRI-ApaI restriction sites and ligated into the pCMV-Sport6 (Invitrogen) expression plasmid. The pCMV-Sport6-cJun expression plasmid was verified with digestion restriction analysis and sequencing.
Luciferase assay. DNA transfections were performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. In short, 2.5610 4 HEK293T cells were seeded 24 h prior to transfection in a 96-well plate. The following day, cells were transfected with a luciferase reporter plasmid (1 ng) and pRL-TK (3 ng) in the presence or absence of pcDNA3-Tat vector (1 or 3 ng) and/or pCMV-Sport6-cJun (2 or 4 ng). To equalize the total amount of DNA for transfection, the empty pcDNA3 vector was used, and to normalize for transfection efficiency, Renilla expression from pRL-TK was used. For the c-Jun overexpression experiments, cells were transfected with 3 ng pcDNA3-Tat vector, and for the TNFainduction cells were transfected with 1 ng pcDNA3-Tat vector. For TNFa treatment, cell culture medium was replaced 18 h postinfection with mock medium or medium supplemented with 10 ng ml 21 TNFa. Cells were harvested 24 h post-transfection and luciferase activity was measured with the DualGlo Luciferase kit (Promega). All transfections were performed in triplicate. Results from different assays were corrected for between-session variation with the factor correction program (Ruijter et al., 2006) .
Western blot. HEK293T cells (0.5610 6 ) were seeded 24 h prior to transfection with the pCMV-Sport6-cJun using Lipofectamine 2000 (Invitrogen). The cells were collected 24 h post-transfection, lysed by dissolving the cells in Laemmli sample buffer and heated at 95 uC for 10 min. Proteins were separated on SDS-PAGE and transferred onto an Immobilin_P membrane (Millipore). Blots were blocked and incubated overnight with the primary antibody followed by incubation with HRP-labelled secondary antibodies. Luminometric detection of proteins was performed with Western Lightning ECL (PerkinElmer Life Sciences) and membranes were analysed on a LAS3000 imager (GE Healthcare).
Virus production and replication. Plasmid DNA encoding the CXCR4-using HIV-1 LAI primary isolate (Peden et al., 1991) or derivatives thereof were transiently transfected into HEK293T cells with the calcium phosphate method as described previously (Das et al., 1999) . Virus supernatant was harvested 2 days after transfection, sterilized by passage through a Whatman 0.2 mm filter (GE Healthcare) and stored in aliquots at 280 uC. The concentration of virus stocks was determined by CA-p24 ELISA. To study viral replication, CD4 + T lymphocytes isolated from two different blood donors were pooled and 1.0610 6 cells were infected with the different isogenic viruses (1 ng CA-p24 for each virus). Supernatant samples of infected cultures were taken on different days for extracellular CA-p24 analysis.
Extracellular CA-p24 ELISA. Culture supernatant was heat inactivated at 56 uC for 30 min in the presence of 0.05 % Empigen-BB (Calbiochem). The CA-p24 concentration was determined by a twin-site ELISA with D7320 (Biochrom) as capture antibody, and alkaline phosphatase-conjugated anti-p24 monoclonal antibody (EH12-AP) as detection antibody. Quantification was performed with the Lumiphos Plus system (Lumigen) in a LUMIstar Galaxy (BMG Labtechnologies) luminescence reader. Recombinant CA-p24 produced in a baculovirus system was used as a standard.
HIV-1 latency assay. HIV-1 infected cells were used in the latency assay as described previously (van der Sluis et al., 2013b) . In short, PHA-activated CD4 + T lymphocytes (2.0610 6 cells) were infected with HIV-1 (20 ng CA-p24). Free virus was washed away after 4 h and the cells were cultured with the fusion inhibitor T1249 (Pepscan) to prevent new infections. At 24 h after infection the cells (1.5610 5 per well) were either mock treated or co-cultured with allogeneic DCs (0.5610 5 per well). After another 24 h, the cells were harvested and intracellular CA-p24 was detected by FACS flow cytometry. The percentage of CA-p24 positive cells in the treated culture was divided by the percentage of CA-p24 cells in the mock-treated culture and used as a measure for proviral latency (fold activation). Oneway ANOVA and Student's t-test (two-tailed) were used to evaluate whether observed differences between groups were significant (Graphpad Prism, version 5). P-values: * P,0.05, ** P,0.01, *** P,0.001.
FACS flow cytometry. Cells were fixed in 4 % formaldehyde for 10 min at room temperature and subsequently washed with FACS buffer (PBS supplemented with 1 % FCS). The cells were permeabilized with BD Perm/Wash buffer (BD Pharmingen), and antibody staining was performed in BD Perm/Wash for 1 h at 4 uC. Excess of unbound antibody was removed and the cells were analysed on a BD FACSCanto II flow cytometer with BD FACSDiva Software v6.1.2 (BD Biosciences) in FACS buffer. The live population was defined based on forward/sideways scatter and analysed for CD3 and intracellular CA-p24 positivity. Gate settings were fixed between samples for each experiment. The DC phenotype [negative for CD14, low levels of MHC class II (HLA-DR), CD83 and CD86 and high levels of DC-SIGN] was confirmed by FACS flow cytometry (Sanders et al., 2002) .
